Early data from a clinical trial in France has demonstrated encouraging profile of Roche unit Genentech’s rheumatoid arthritis drug tocilizumab (Actemra) to treat seriously ill Covid-19 patients.
The study, which was conducted by the Paris university hospital trust (AP-HP), involved 129 hospitalised patients with moderate or severe viral pneumonia.
Related Articles
Related Companies
